NASDAQ:TNXP

Tonix Pharmaceuticals Stock Forecast, Price & News

$0.98
-0.06 (-5.77 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.94
Now: $0.98
$1.01
50-Day Range
$0.97
MA: $1.22
$1.50
52-Week Range
$0.51
Now: $0.98
$2.46
Volume13.31 million shs
Average Volume36.70 million shs
Market Capitalization$317.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.
Tonix Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155
Employees16
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.11 per share

Profitability

Net Income$-28,620,000.00

Miscellaneous

Market Cap$317.44 million
Next Earnings Date5/11/2021 (Estimated)
OptionableOptionable

Headlines

2 Best Reddit Healthcare Stocks to Buy Now
April 15, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

122nd out of 2,021 stocks

Pharmaceutical Preparations Industry

48th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$0.98
-0.06 (-5.77 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

Is Tonix Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Tonix Pharmaceuticals?

Wall Street analysts have given Tonix Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tonix Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,630,000 shares, an increase of 44.0% from the March 15th total of 3,910,000 shares. Based on an average daily trading volume, of 38,120,000 shares, the short-interest ratio is presently 0.1 days.
View Tonix Pharmaceuticals' Short Interest
.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Tonix Pharmaceuticals
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced its earnings results on Sunday, March, 14th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.03.
View Tonix Pharmaceuticals' earnings history
.

How has Tonix Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TNXP shares have increased by 17.9% and is now trading at $0.98.
View which stocks have been most impacted by COVID-19
.

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Tonix Pharmaceuticals's stock reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for TNXP?

1 equities research analysts have issued 1 year price targets for Tonix Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Tonix Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 308.2% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 63, Pay $783.1k)
  • Mr. Bradley Saenger CPA, CPA, CFO & Treasurer (Age 47, Pay $465.85k)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 55, Pay $484k)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.
  • Dr. Herbert W. Harris, Exec. VP of Translational Medicine
  • Dr. Daniel J. Clauw, Consultant
  • Dr. R. Michael Gendreau, Consultant (Age 65)

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (0.01%). Company insiders that own Tonix Pharmaceuticals stock include Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends for Tonix Pharmaceuticals
.

Which major investors are buying Tonix Pharmaceuticals stock?

TNXP stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Gregory M Sullivan, James Treco, Margaret Smith Bell, and Seth Lederman.
View insider buying and selling activity for Tonix Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.98.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals has a market capitalization of $317.44 million. The company earns $-28,620,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals employs 16 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is www.tonixpharma.com.

Where are Tonix Pharmaceuticals' headquarters?

Tonix Pharmaceuticals is headquartered at 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.